Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment This is an open-access article distributed under the terms of the Creative Commons Attribution License CBD benefits are widely discussed, but whether CBD for IBS is a viable treatment option is still being studied. However, here’s what early research says.
Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Irritable Bowel Syndrome (IBS) is a functional disorder characterized by abdominal pain, spasms, and altered bowel movements, either predominantly diarrhea (IBS-D), or predominantly constipation (IBS-C), or alternating between those states (Saha, 2014). In the Western world it affects the 10–15% of the population (Canavan et al., 2014). IBS represents a visceral hypersensitivity, with features of gastrointestinal (GI) allodynia and hyperalgesia. Considered a life-long condition, it is clear that significant gastrointestinal insults, such as food poisoning or antibiotic administration, may generate attacks that persist, often indefinitely. Attacks are associated with anxiety and depression, but controversy carries on to which incites the other (Saha, 2014). It is possible that some patients may develop a vicious cycle of worsening physical and psychological symptoms (Jones et al., 2013, 2017).
Currently, IBS sufferers are prescribed opioids, anticholinergics, and antidepressants, however with quite suboptimal results. Other compounds have been formulated to interact with serotoninergic circuitry, nevertheless these have been withdrawn from certain markets due to association with ischemic colitis (alosetron, cilansetron) and cardiovascular events (tegaserod), leaving, de facto, an urgent clinical need (Ford et al., 2014; Lexicomp Online, 2017).
The Endocannabinoid System (ECS) is known to modulate several functions, including mood, anxiety, and memory retrieval of traumatic events and it directly coordinates GI propulsion, secretion, inflammation, and nociception, providing a rationale for agents capable of interacting with the ECS as treatment candidates for IBS (Russo, 2016).
Irritable Bowel Syndrome and the Endocannabinoid System
Endocannabinoid System in the Bowel
The ECS is ubiquitously expressed in the human body and it actively controls gut homeostasis. The best characterized ECS receptors are the cannabinoid receptors 1 (CB1) and 2 (CB2) (Mackie, 2005).
CB1 has been found in intestinal epithelial and in the enteric nervous system (ENS) (Coutts and Izzo, 2004).
Physiologically, the activation of presynaptic CB1 attenuates large and small bowel muscle tone and inhibits GI motility, mainly by reducing the release of acetylcholine from enteric nerves and also by inhibiting all the components of the peristaltic reflex (Wright et al., 2005). Moreover, CB1 activation, via the purinergic system, inhibits spontaneous ileal contractions and modulate the activity of vagal neurotransmission, reducing intestinal peristalsis (DiPatrizio, 2016).
CB2 has been found on enteric neurons but it is predominantly expressed by intestinal immune cells (Izzo, 2007). Targeting intestinal CB2 decreases inflammation through the reduction of cytokine and chemokine production from activated immune cells (Wright et al., 2008). In pathophysiological conditions, CB2 controls intestinal motility (Wright et al., 2008) and its activation slows down gut transit (Mathison et al., 2004).
Bot1 and CB2 have been identified in the intestinal neuronal circuitry of the transmission of visceral pain and their activation reduce visceral sensation and nociception (Hohmann and Suplita, 2006).
N-arachidonoylethanolamine (anandamide, AEA) and 2-arachidonoyl glycerol (2-AG) are the best characterized endocannabinoids; they are synthesized from membrane phospholipids on demand: AEA is synthesized by N-acyl-phosphatidylethanolamine phospholipase D (NAPE-PLD); and 2-AG by diacylglycerol lipase (DAGL), then they are released and induce a local response by activating CB1 and/or CB2 receptors (the latter being involved mainly in pathophysiological conditions) (Izzo and Camilleri, 2008). These compounds are involved in the control of food intake and hunger (DiPatrizio, 2016; Lee et al., 2016). Specifically, AEA seems to regulate appetite and energy balance, while 2-AG may serve as a general hunger signal (Di Marzo and Matias, 2005; DiPatrizio, 2016). AEA, via CB2, plays also a pivotal role in maintaining immunological health in the gut (Acharya et al., 2017).
Subsequent to their activation, endocannabinoids are inactivated by reuptake from the degradative enzymes fatty acid amide hydrolase (FAAH), located in cells of the myenteric plexus and monoacylglycerol lipase (MAGL), present in the nerve cells and fibers throughout the muscle mucosal layers of the intestine (Di Marzo, 2006).
Inhibition of MAGL and FAAH in the gut significantly reduces experimental colitis in mice, through mechanisms that involve a rise in 2-AG or AEA levels, respectively, and the stimulation of both CB1 CB2 signaling (Massa et al., 2004; Sałaga et al., 2014; Vera and Fichna, 2017).
N-palmitoylethanolamine (PEA) and other N-acylethanolamides (NAEs) are also expressed in the gut (Izzo and Sharkey, 2010). NAEs are atypical endocannabionoids: their structures resemble the classical endocannabinoids and they are preferentially metabolized by FAAH, but they do not bind CB receptors (Izzo and Sharkey, 2010; Ahn et al., 2014). NAEs, especially PEA, are involved in the control of various functions, including food intake, neuroprotection, nociception, and inflammation (Suardíaz et al., 2007; Ahn et al., 2014; Lowin et al., 2015).
Other components of the ECS are the transient receptor potential (TRP) channels, such as TRPV1, TRM8, and others (Storozhuk and Zholos, 2018). These receptors, widely expressed throughout the digestive tract, are involved in numerous processes: taste, chemo- and mechanosensation, thermoregulation, pain and hyperalgesia, mucosal function, gut homeostasis, and control of motility, amongst others (Kaneko and Szallasi, 2014).
GPR55, another potential cannabinoid receptor, seems to be also implicated in gut motility. Its inhibition reduce motility in mice and this effect was reversed by cannabidiol (CBD), but not by CB1 or CB2 receptor antagonists (Li et al., 2013).
The ECS is also an important modulator of the gut-brain axis. In the gut, receptors of the ECS (especially TRPs) are involved in sensory transduction of a large number of external and noxious stimuli (Holzer, 2011). In the brain, the ECS controls nausea and vomiting, especially through CB1 receptors in the dorsal vagal complex of the brainstem, and stress-induced alterations of the ECS have been linked to altered visceral sensations (Sharkey and Wiley, 2016).
The main role of ECS in the GI tract is controlling intestinal hyper-contractility. Moreover, it modulates visceral sensations, intestinal inflammation and gut–brain communications, all functions that appear to be dysregulated in IBS.
IBS and Endocannabinoid Deficiency
Clinical Endocannabinoid Deficiency (CED) has been confirmed as a plausible feature in a series of difficult-to-characterize psychosomatic pathologies, which display hyperalgesia, anxiety, and depression (Russo, 2004, 2016); Migraine, fibromyalgia and IBS fall in this category, often showing comorbidity in the three diagnosis (Nicolodi and Sicuteri, 1996; Sperber et al., 1999; Peres et al., 2001). CED occurs either as a congenital disorder, or as a result of epigenetic changes.
IBS subtypes exhibit distinct variations of the ECS tone. IBS-D patients show genetic alterations affecting endocannabinoid metabolism, variants of the CNR1 and FAAH genes, and lower levels of Oleoylethanolamine (OEA) and PEA compared to healthy subjects (Fichna et al., 2013). Specifically, the CNRI rs806378 CT/TT genotype shows a significant association with colonic transit in IBS-D (Camilleri et al., 2013). Conversely, IBS-C patients show levels of OEA higher than healthy volunteers, and reduced levels of FAAH mRNA in intestinal tissues (Fichna et al., 2013).
Some of these changes may occur as the result of chronic stress, which profoundly impacts the ECS: it silences the Cnr1 gene promoter via an increased methylation by DNA (cytosine-5)-methyltransferase 1, but it also activates the Trpv1 promoter via acetylation (Hong et al., 2015). This results in reduced levels of CB1 and increased levels of TRPV1 in the sensory neurons localized in the pelvic organs, including the colon, which is a feature of visceral pain, as later discussed (Fichna et al., 2013).
Stress in the early-life stage is also an important contributor to IBS development and it is associated with epigenetic changes that lead to visceral hypersensitivity (Moloney et al., 2015). Maternal deprivation increases the expression of the endocannabinoid genes Cnr1, Cnr2a, Cnr2b, and GPR55 in the frontal cortex of male rats, whereas in female rats, increased expression was reported only in the hippocampus, a difference that may underline the prevalence of IBS in the female population (Marco et al., 2014). The relevance of pediatric stress in IBS is supported by the fact that infantile colitis, characterized by visceral sensitivity and dysphoria and resistant to most pharmacotherapies, seem to be offset by the endocannabinoids present in maternal milk, reason for it is hypothesized that this condition may also be a CED (Russo, 2004). Taken these data together, genetic polymorphisms and alterations in gene expression are associated with disturbances in GI motility and sensation, supporting the pathophysiologic significance of alterations in the ECS in the gut (Moloney et al., 2015).
Utilizing ECS-Modulating Agents for IBS
Gut health devoid of pain and maintenance of balanced body weight seems to require a complex interplay between diet, enteric flora, and endocannabinoid balance (Clarke et al., 2012; Russo, 2016). Oral administration of Lactobacillus acidophilus NCFM induce a direct increase of the cannabinoid receptors CNR2 mRNA (Rousseaux et al., 2007). This result corresponded with an enhancement of morphine analgesic effect in rats, which was inhibited by administration of the CB2 antagonist, AM-630 (Rousseaux et al., 2007). Cannabinoids may also directly alter the microfloral balance, as underscored by the finding that THC affected the Firmicutes:Bacteroidetes ratio in obese mice, preventing their weight gain despite a high-fat diet (Cluny et al., 2015).
The interaction of the microbiome–gut–brain axis is highly dependent on hypothalamic–pituitary–adrenal (HPA) stress modulation, which is dysregulated in IBS patients (Chang et al., 2009). The ECS regulates basal and circadian HPA axis activation (Patel et al., 2004; Liedhegner et al., 2014), and these changes relate to the differences in visceral sensation that feature in IBS (Gschossmann et al., 2001). Linkage of the cannabinoid–vanilloid pathway to the HPA axis has been demonstrated by experiments monitoring rats inoculated with corticosterone, mimicking chronic stress, which developed visceral hyperalgesia (Hong et al., 2011); moreover, as also shown by another stressed rat model (Hong et al., 2009), the levels of AEA and the expression and phosphorylation of TRPV1 increased in the animals, whilst CB1 expression decreased in lumbosacral primary afferent neurons localized in the colon, but not in those innervating the lower extremities (Hong et al., 2009, 2011). AEA is an endogenous agonist at both CB1 and TRPV1 (McPartland et al., 2007), receptors that co-localize in nociceptive primary sensory neurons (Ahluwalia et al., 2000). Activation of CB1 inhibits nociception, whereas agonism at TRPV1 increases pain perception (Malik et al., 2015). Treatment of stressed rats with the CB1 agonist WIN 55,212-2 or the TRPV1 antagonist capsazepine prevented visceral hyperalgesia (Hong et al., 2009). Similar data have been observed in biopsies from IBS sufferers, which show a 3.5-fold elevation in TRPV1-immunoreactive nerve fibers (Akbar et al., 2008).
Considering this evidences, it has been posited that chronic stress causes down-regulation or loss of CB1, activation of the HPA stress response, anxiety, and induces visceral hyperalgesia that involve region-specific changes in endovanilloid and endocannabinoid pathways in sensory neurons innervating the pelvic viscera (Morena et al., 2016). Thus, a rationale exists for the use of compounds that boost AEA and PEA levels and desensitize TRPV1, to treat hypersensitivity and pain in IBS. While some authors have encouraged the use of the phytocannabinoid cannabidiol (CBD), no clinical trials have tested this hypothesis (Russo, 2004; Pandey et al., 2020). CBD may be an useful therapeutic intervention as it desensitizes TRPV1 and inhibits PEA and AEA hydrolysis and uptake (Bisogno et al., 2001).
Targeting endocannabinoid-degrading enzymes to increase AEA may be an interesting model (Sakin et al., 2015), given their role in the tonic disinhibition of periaqueductal gray region of the brainstem to promote analgesia and chronic stress-induced anxiety (Lau et al., 2014; Sakin et al., 2015). A dual FAAH and COX inhibitor has been shown to increase AEA and PEA levels, reducing features of colitis in mice (Sasso et al., 2015).
Clinical Trials With ECS-Acting Agents
Despite the numerous lines of evidence showing the involvement of ECS in the regulation of IBS features and the promising data from pre-clinical studies, few clinical trials tested the effect of ECS-modulating agents in IBS.
On the other hand, ECS alteration in IBS patients has been clearly documented.
As ECS is known to decrease motility, effects of dronabinol, a non-selective agonist of the cannabinoid receptors, have been tested on IBS patients (Wong et al., 2011). In a 2011 clinical trial, dronabinol reduced fasting colonic motility in all IBS-D patients, particularly those carrying the CB1 receptor polymorphism rs806378 (Wong et al., 2011). Another clinical study carried out a few years later, failed to replicate these results, obtaining only modest delay in motility, maybe for differences in methods (manometry vs. radioscintigraphy) and the lower number of patients enrolled (Wong et al., 2012). Dronabinol can also improve visceral sensitivity and colonic relaxation, as showed in a double-blind, placebo-controlled trial (Esfandyari et al., 2007).
As mentioned before, Fichna et al. showed that lower PEA levels are associated with cramping abdominal pain (Fichna et al., 2013). A randomized placebo-controlled multicenter study assessing the efficacy of PEA in IBS, revealed that PEA may be an useful tool for pain management in this condition (Barbara et al., 2014).
Since visceral hypersensitivity is linked to an increase in Ts regard, a 2011 pilot study found that ingesting capsaicin-containing enteric-coated pills desensitized TRPV1 and decreased the intensity of abdominal pain and bloating in IBS patients vs. placebo (Bortolotti and Porta, 2011). Another study confirmed that TRPV1 desensitization reduced visceral hypersensitivity, symptoms, and abdominal pain (Wouters et al., 2016).
Menthol-induced analgesia and pain relief is mediated mainly by TRPM8 (Liu et al., 2013). This is the rationale for various trials that analyzed the efficacy of peppermint oil (containing menthol) in IBS. Even with some limitations mainly due to the delivery system of peppermint oil in the digestive tract, it turned out an effective treatment capable of improving IBS symptoms, especially abdominal pain, even in children suffering IBS (Kline et al., 2001; Cappello et al., 2007; Merat et al., 2010; Cash et al., 2016).
Although the pathophysiology of IBS remains unclear, targeting the ECS may represent a promising strategy to modulate gut motility, visceral hyperalgesia, low-grade intestinal inflammation, and gut–brain axis alteration, all features that may improve IBS symptoms onset. It is also evident that both an IBS-diet (Wouters et al., 2016) and a stress-relief practice are required to boost the beneficial effects of any of the agents suggested.
In light of this, agents capable of modulating the ECS may provide a strategy worth attempting even first line treatment for IBS patients ( Figure 1 ). This is due to the fact that compounds such as PEA, CBD and peppermint oil display a very large safety profile and have been proving beneficial to improve IBS symptoms (Halford et al., 2018); PEA, peppermint oil, THC and its synthetic analogs may be recommended in IBS patients to improve abdominal spasms, cramps and visceral pain. THC and CBD may alter ECS-driven response to the pathology. However, there is still a wide gap in the current understanding of IBS mechanism and in the use of cannabis containing both CBD and THC as potential therapy, which can only be bridged by randomized clinical trials.
IBS features modulated by ECS. Schematic representation of the Endocannabinoid System (ECS) involvement in lBS features and its interaction with hypothalamic-pituitary-adrenal (HPA) axis throughout day/night. The black arrows indicate the receptors and the target sites controlled by ECS components. In red are shown the agents capable of modulating ECS activities that may be useful to improve IBS symptoms, such as motility, visceral pain, and low-grade inflammation. Blue arrows indicate a decrease in the functions targeted by ECS stimulation. TRPV I, Transient receptor potential vanilloid I; CB I, Cannabinoid Receptor I; CB2: Cannabinoid Receptor 2; TRPM8, Transient receptor potential melastatin 8; CBD, cannabidiol; THC, tetrahydrocannabinol; FAAH, fatty acid amide hydrolase; COX, cyclooxigenase; MAGL, monoacyl glycerol lipase; PEA, palmitoylethanolamide; PPARa: Peroxisome proliferator-activated receptor a.
VB and FT contributed to conception and design of the study and wrote sections of the manuscript. VB wrote the first draft of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors would like to acknowledge the contribution of Adrian Devitt-Lee, University College of London.
What You Need to Know About Using CBD for IBS
The Curious Role of the Endocannabinoid System in Gut Health
With the increasing legalization of cannabis and its by-products in the United States, CBD oil — otherwise known as cannabidiol — is everywhere. You can find it in gas stations, grocery stores, as well as in specialty boutiques and cannabis dispensaries, and it’s recommended for a wide range of health concerns.
One of the things CBD is recommended for is Irritable Bowel Syndrome (IBS). Some early research suggests that CBD may be able to influence your gut inflammation, motility, and even your gut microbiome. Is CBD for IBS a valid treatment option?
Currently, there is almost no direct research suggesting that CBD can improve IBS symptoms.
Let’s explore what CBD is, what we know about the effects of CBD for IBS and the digestive system, and what we know and don’t know about how it may treat Irritable Bowel Syndrome (IBS) or other digestive conditions.
What Is CBD?
Cannabidiol (CBD) is one of many cannabinoids, which are cannabis plant compounds produced by Cannabis sativa and hemp plants. CBD is non-intoxicating and non-psychoactive. CBD’s more famous cousin, THC (tetrahydrocannabinol), is the cannabinoid responsible for the well-known psychoactive effects of smoking or consuming cannabis.
Companies that sell CBD products promote it to help remedy a wide range of health concerns, such as chronic pain [ 1
Trusted Source PubMed Go to source ], headaches, joint pain, appetite, sleep, and digestive complaints like IBS.
CBD appears to be able to act as a pain reliever and has anti-inflammatory properties several hundred times stronger than aspirin . However, there is a tendency to generalize claims about full-spectrum cannabis — extracts of whole cannabis — and CBD alone. To more fully explain, we need to dive into the specifics of the endocannabinoid system.
Endocannabinoid System 101
It may surprise you to learn that the human body creates its own cannabinoids and has a vast network of cannabinoid receptors.
This means your body is wired to benefit from cannabinoids. This endocannabinoid system (ECS) plays an important role in the development, balancing, and resilience of your central nervous system and immune system [3, 4
There are two main types of cannabinoid receptors: CB1, and CB2. CB1 receptors are concentrated primarily in your brain and peripheral nervous system, while CB2 receptors are located not only in your brain and nervous system but also in your digestive and immune systems [ 5
Trusted Source PubMed Go to source ]. CBD can bind to either type of cannabinoid receptor.
Some researchers have proposed that endocannabinoid deficiency may influence gut conditions like IBS, pain conditions, such as fibromyalgia and migraines [ 6
Trusted Source PubMed Go to source ], as well as autoimmune diseases [ 7
Trusted Source PubMed Go to source ]. Endogenous cannabinoids (meaning those produced by your body), like anandamide, are thought to influence pain perception and gut motility (the movement of waste through your digestive tract) [ 8
Trusted Source PubMed Go to source ]. For this reason, many people are excited about the potential of cannabinoids like CBD to help chronic pain, opioid addiction, and IBS symptoms like bloating, constipation, and hypersensitivity [ 9
CBD for IBS (Irritable Bowel Syndrome)
Irritable bowel syndrome (IBS) is a common digestive tract disorder. Frequent digestive systemsymptoms of IBS include [ 10
- Abdominal pain or cramping
- Diarrhea or loose stool (IBS-D), or constipation (IBS-C)
- Food sensitivities
The root causes of IBS vary widely, from bacterial overgrowth to nervous system imbalances that affect gut motility. Because of this, treating IBS requires a multi-faceted approach.
Many people with other digestive conditions — such as Inflammatory Bowel Diseases like Crohn’s disease and ulcerative colitis — also have IBS symptoms.
Does CBD Help IBS?
There is not yet clear evidence that CBD can help IBS symptoms, despite some interesting preliminary results and hopeful theories.
In the end, dietary changes such as a low FODMAP diet [ 11
Trusted Source PubMed Go to source ] have proven and documented benefits for IBS where you don’t have to wait for further research. So, while we explore the research so far about CBD and IBS, please don’t ignore more proven approaches.
Multiple literature reviews suggest that targeting the endocannabinoid system with CBD or other cannabinoids may provide some benefit for IBS patients and their symptom flare-ups, as well as patients with other gastrointestinal disorders such as inflammatory bowel disease (IBD) [ 16
However, there is little direct clinical evidence to suggest you are likely to benefit from CBD if you have IBS symptoms..
Here is a summary of the evidence that suggests CBD may be beneficial for IBS symptoms:
In a large observational study, CBD was associated with reduced gut and non-specified pain [ 19
Trusted Source PubMed Go to source ], normalize both slow and fast gut motility , and positively affect nerve channels that regulate gut motility and secretion [ 25
Out of all these studies, only two are placebo-controlled clinical trials. The rest are lower quality observational, or animal studies, which may or may not have relevance for humans, and none of them specifically studied IBS. So even though these are positive findings, they are not a clear endorsement of CBD.
Add to that the following study results, which don’t support using CBD for IBS symptoms:
A 2021 SR/MA of 15 nonrandomized studies and 5 RCTs concluded that cannabinoids do not induce clinical remission or affect inflammation in IBD patients (although there may be some improvement in symptoms) [ 27
Using CBD for IBS
CBD oil is allowed to be sold throughout the United States as long as the THC content is below 0.3%. People typically consume CBD products orally as an oil, but they can also be consumed as a tincture (a preparation of CBD in alcohol or glycerin) or edible product (like a gummy or baked good).
In states where cannabis is legal, either for medicinal or recreational use, some CBD products may contain varying levels of THC. Some evidence suggests that therapeutic results are better when CBD is given together with other cannabinoids, including THC [ 30
Trusted Source PubMed Go to source ]. This is known as the “entourage effect.” However, not everyone wants the psychoactive side effects of THC. Read your labels carefully, or request help interpreting the information on product labels.
Your ideal dosage will vary widely depending on your body’s needs, the potency of the product, and your tolerance. For best results, consult with a health care provider or medical professional who is knowledgeable about CBD dosing and your medical condition.
CBD Oil Side Effects and Safety
If you want to try CBD for IBS, keep the following considerations in mind.
CBD Side Effects
CBD is often promoted as a safer alternative to medications, but some people do experience side effects.
CBD and other cannabinoids are metabolized in the liver and intestines.
Too much CBD can damage the liver, especially if mixed with other medications, such as leflunomide, lomitapide, mipomersen, pexidartinib, teriflunomide, and valproate . If you are taking these medications or have an existing liver condition, consult a physician before using CBD.
CBD oil consumption can cause possible side effects [ 32
Trusted Source PubMed Go to source ]. These include:
- Nausea or vomiting
- Diarrhea 
- Decreased appetite
- A minority of people may have an intolerance to cannabis oil or its carrier oils such as sesame oil.
A systematic review and meta-analysis found that adverse gastrointestinal tract events may be more common when CBD and other cannabis-based medicines are ingested rather than inhaled [ 36
Non-FDA-approved CBD products on the market vary greatly in quality and consistency. This raises two potential issues:
Without independent laboratory verification, one cannot know whether the dosage of such products is accurate, if the THC content is less than 0.3%, and whether they are unadulterated and uncontaminated [ 37
Always buy CBD products from manufacturers who are transparent about their production methods, quality-control measures, and potency. Look for independent laboratory verification of product contents.
Probiotics and the Endocannabinoid System
Some very early evidence suggests that the gut microbiome may influence the endocannabinoid system [ 38
One clinical study showed that Lactobacillus probiotic supplementation increased the function of cannabinoid and opioid receptors and reduced pain [ 39
Trusted Source PubMed Go to source ]. Dogs with motility problems who were given probiotics showed an increase in cannabinoid receptor action and improved motility [ 40
Trusted Source PubMed Go to source ]. Another study, albeit in mice, suggested that CBD increased the abundance of beneficial gut bacteria but also increased the expression of inflammatory cytokines [ 41
We know that probiotics are a clinically effective treatment option for a wide range of digestive complaints [ 42
Trusted Source PubMed Go to source ]. We don’t need to know whether their interaction with the endocannabinoid system is one more reason for their benefits, but it’s an interesting line of research for the future.
The Truth About CBD for IBS
CBD may be popular, but there isn’t yet proof that it helps IBS symptoms. While early data suggest it may play a helpful role in regulating gut motility, reducing gut pain, and supporting the nervous system, much more research is needed.
There are many proven and effective treatments for IBS, and it makes sense to keep your focus on these approaches. However, If you’re CBD curious, try CBD as a short-term trial and don’t expect miracles.